Truvian’s website articulates the promise of its desktop blood-testing analyzer thus: “A few drops of blood. No send outs. Fully automated. Accurate results in minutes.”
It has echoes of the sorts of claims that brought down Bay Area startup Theranos Inc., a tale that Truvian CEO Jay Srinivasan knows well. But he is bullish about his San Diego-based company’s technology and his vision for making decentralized testing widely available, pointing to recently published data showing results from Truvian’s on-site blood diagnostics platform to be largely consistent with those generated by large central labs, as well as high interest among investors
Key Takeaways
-
A multi-study site showed that Truvian’s benchtop instrument achieved closely matched readings when compared to large instruments used in centralized laboratories for almost all assays in its panel